Nutriband Inc. Advances Abuse-Deterrent Drug Delivery with Fentanyl and Buprenorphine Candidates

Nutriband Inc. (NASDAQ: NTRB) is leading the charge in the development of abuse-deterrent drug delivery systems, with its AVERSA technology at the core of its innovative approach. The company's flagship products, AVERSA Fentanyl and AVERSA Buprenorphine, are designed to combat the abuse and misuse of transdermal patches, offering a significant advancement in public health safety. AVERSA Fentanyl, potentially the first opioid patch of its kind, could see peak annual U.S. sales ranging from $80 to $200 million, while AVERSA Buprenorphine is projected to achieve between $70 and $130 million in peak U.S. sales upon approval. These developments are supported by Nutriband's scalable platform, which is on track for global patent protection, marking a pivotal moment in the fight against drug abuse and accidental exposure.